Cholangiocarcinoma — Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors
Citation(s)
Lenvatinib Combined Pembrolizumab as a Second-line Treatment in Advanced Hepatobiliary Tumors: a Single-center, Single-arm, Non-randomized Clinical Study